Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?-Reference-Cited by-同舟云学术

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?

Published:2017-07-05 Issue:18 Volume:123 Page:3450-3459
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Tomao Federica¹,D'Incalci Maurizio²,Biagioli Elena²,Peccatori Fedro A.³,Colombo Nicoletta⁴⁵^ORCID

Affiliation:

1. Department of Gynecological; Obstetrical and Urological Sciences, “Sapienza” University; Rome Italy

2. Department of Oncology; Mario Negri Institute for Pharmacological Research, Scientific Institute for Research, Hospitalization, and Health Care (IRCCS); Milan Italy

3. Fertility and Procreation Unit, European Institute of Oncology, Institute for Treatment and Research (IRCCS); Milan Italy

4. Department of Gynecologic Oncology; European Institute of Oncology, Institute for Treatment and Research (IRCCS); Milan Italy

5. Department of Surgical Sciences; University of Milan Bicocca; Milan Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30830/fullpdf

Reference53 articles.

1. Clinical trials in recurrent ovarian cancer;Friedlander;Int J Gynecol Cancer.,2011

2. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease;Wilson;Ann Oncol.

3. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer;Bolis;Gynecol Oncol.,2001

4. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet.,2003

5. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study;Gonzalez-Martin;Ann Oncol.,2005

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer;Current Cancer Drug Targets;2024-07

2. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer;Medicine;2024-05-17

3. Heterogeneity and treatment landscape of ovarian carcinoma;Nature Reviews Clinical Oncology;2023-10-02

4. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments;European Journal of Cancer;2023-09

5. Epithelial Ovarian Cancer: A Five Year Review;Medicina;2023-06-21